MYOK has caught our attention after selling off on key data and bouncing off a key support level. Also, key data reported yesterday was positive. Here are the highlights:
A 59-subject Phase 2 clinical trial, MAVERICK-HCM, evaluating MyoKardia's (NASDAQ:MYOK) mavacamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM) (the walls of the ventricles thicken compromising blood flow) met the primary endpoint of safety at week 16.
Meaningful reductions in cardiac stress biomarkers were also noted. The results will be submitted for presentation at a future medical conference.
The company intends to launch additional studies in patients with non-obstructive HCM (will provided a regulatory update in H1 2020) and heart failure with preserved ejection fraction (Phase 2 study should commence in Q2 2020).
On another note, new data from its PIONEER open-label extension study of mavacemten in symptomatic obstructive HCM showed consistent results at week 48 (12 participants) compared to weeks 12, 24 and 36.
Shares closed down 7% after the 5% runup at the end of last week.
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
As always, trade with caution and use protective stops.